Full-Time

Senior Financial Analyst

Posted on 11/21/2025

Deadline 3/2/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$75k - $100k/yr

+ Bonus + Equity

Chicago, IL, USA

Hybrid

Three days per week in-office required.

Category
Finance & Banking (1)
Required Skills
Inventory Management
Forecasting
Financial analysis
Excel/Numbers/Sheets
Financial Modeling
Requirements
  • Bachelor’s Degree in Finance, Accounting, Supply Chain Management or a related field
  • 3-5 years of experience in FP&A or corporate finance, ideally within pharmaceuticals, biotech, life sciences, or manufacturing
  • Advanced Excel and financial modeling skills
  • Familiarity with FP&A systems
  • Strong analytical, organization, presentation and communication skills
  • Ability to manage multiple priorities and meet deadlines in a fast-paced environment
  • Competencies: Methodical, Detail-oriented, Interpersonal skills, Written and Verbal Communication skills, Strategic, Professionalism, Organizational skills, Self-directed, Teamwork, Adaptability
  • Working Conditions: Position may require periodic evening and weekend work, as necessary to fulfill obligations. Periodic overnight travel.
  • This is a hybrid role based in Xeris’ Chicago office and requires a minimum of three days per week in the office. On-site requirement may change at management’s discretion.
  • The level of the position will be determined based on the selected candidate’s qualifications and experience.
Responsibilities
  • Lead the annual budgeting and quarterly forecasting processes across commercial and lifecycle management manufacturing teams
  • Prepare and update detailed expense templates and forecasts; consolidate departmental inputs for review
  • Collaborate with FP&A leadership to ensure all financial assumptions are accurate and consistent with company objectives
  • Present financial data to all levels of the organization to highlight important drivers and metrics
  • Support cash balance projection process through calculation of cash flow impacts related to procurement and production of commercial products
  • Support quarterly and annual COGS forecasting processes for commercial products
  • Develop and maintain cost models to project product gross margins under various volume and pricing scenarios
  • Analyze actual vs. forecasted manufacturing costs, including material, labor, and overhead variances
  • Provide insights into COGS trends and drivers for management and investor reporting
  • Partner with Accounting to lead standard cost setting process leveraging information contained in supplier contracts and production forecasts
  • Collaborate with Supply Chain and Technical Operations to track and forecast inventory levels across raw materials, WIP, and finished goods
  • Monitor inventory obsolescence, write-offs, and production yields, providing timely financial impact assessments, including proactive tracking and communication of risks and opportunities
  • Support monthly close activities by reconciling inventory balances and COGS entries with Accounting and prepare analysis on key variance drivers
  • Help develop and refine inventory reporting tools to improve visibility and accuracy
  • Act as a financial partner to Supply Chain, Manufacturing, and Quality functions.
  • Support budgeting and expense tracking for internal manufacturing and external contract manufacturing organizations (CMOs).
  • Assist with financial evaluations of supply agreements, purchase requests, production decisions, and capacity planning initiatives
  • Support the FP&A team in maintaining accurate COGS and inventory components within the corporate financial model
  • Contribute to process improvements to increase forecasting efficiency and reporting quality, including supporting FP&A system implementation and maintenance
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $49.8 million in Q1 2026.
  • Xeris raised 2026 revenue guidance to $380 million-$390 million after strong Q1.
  • XP-8121 remains on track for Phase 3 initiation later in 2026.

What critics are saying

  • Gvoke faces Medicare coverage pressure, keeping revenue flat at $20.8 million.
  • Recorlev faces generic litigation threats from two applicants targeting March 2040 patents.
  • XP-8121 remains pre-Phase 3, leaving Xeris dependent on current marketed products.

What makes Xeris Pharmaceuticals unique

  • Xeris builds ready-to-use liquid-stable injectables through XeriSol and XeriJect.
  • Gvoke replaces multi-step glucagon mixing with pre-filled syringe and auto-injector options.
  • Recorlev and Keveyis target rare endocrine and neuromuscular diseases with limited competition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Xeris Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

0%

2 year growth

2%
Living Vision International Ministries
May 7th, 2026
Xeris Biopharma: Q1 earnings snapshot.

Xeris Biopharma: Q1 earnings snapshot. CHICAGO (AP) - CHICAGO (AP) - Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported first-quarter net income of $2.2 million. On a per-share basis, the Chicago-based company said it had profit of 1 cent. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was breakeven on a per-share basis. The company posted revenue of $83.1 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $80 million. Xeris Biopharma expects full-year revenue in the range of $380 million to $390 million. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XERS at https://www.zacks.com/ap/XERS

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.

INACTIVE